This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Study of GS-2426 in Participants With Advanced Solid Tumors | MicrobiomeTrials
← Back to trials NCT07601243
Study of GS-2426 in Participants With Advanced Solid Tumors Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-06-02Est. Completion: 2029-01
Enrollment target: 174 participantsLocations Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States START Midwest, Grand Rapids, Michigan, United States START Astera, LLC, East Brunswick, New Jersey, United States Memorial Sloan Kettering Cancer Center, New York, New York, United States START San Antonio, LLC, San Antonio, Texas, United States START Madrid- CIOCC - Hospital HM Sanchinarro, Madrid, Spain Other microbiome trials you might be interested in Carcinoma, Non-Small-Cell Lung
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet…
Birmingham, United States Est. completion Sep 7, 2029
Small Cell Lung Cancer Large Cell Neuroendocrine Lung Carcinoma Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
This study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 part…
Washington D.C., United States Est. completion Apr 26, 2030
Advanced Solid Tumor (Phase 1)
This is a Phase 1, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharma…
Shanghai, China Est. completion Dec 30, 2028